Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$892K Buy
4,102
+1
+0% +$222 0.46% 67
2025
Q4
$937K Buy
4,101
+26
+0.6% +$5.92K 0.48% 61
2025
Q3
$944K Buy
4,075
+107
+3% +$21.8K 0.5% 55
2025
Q2
$737K Sell
3,968
-58
-1% -$10.8K 0.42% 66
2025
Q1
$844K Buy
4,026
+1
+0% +$194 0.51% 59
2024
Q4
$715K Buy
4,025
+1,772
+79% +$326K 0.42% 70
2024
Q3
$445K Buy
+2,253
New +$420K 0.27% 90

Other funds holding ABBV

Tudor Financial's ABBV Position: Q1 2026 in Review

Tudor Financial increased its AbbVie (ABBV) stake by 0.02% in Q1 2026, buying an estimated $222 and bringing the position to 4,102 shares worth $892K. The position accounts for 0.46% of the portfolio, ranked #67.

Tudor Financial first reported a position in ABBV in Q3 2024 and has held it in 7 quarters since. The position peaked at $944K in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Tudor Financial held 4,102 shares of AbbVie worth $892K as of Q1 2026.
  • Tudor Financial bought 1 AbbVie share in Q1 2026, an estimated $222.
  • AbbVie made up 0.46% of Tudor Financial's portfolio in Q1 2026, its #67 holding.
  • Tudor Financial first reported a position in AbbVie in Q3 2024 and has held it in 7 quarters since.
  • Tudor Financial's AbbVie position peaked at $944K in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Tudor Financial's 13F filing for Q1 2026, filed 14 May 2026.